Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo to patients in France, Denmark, Iceland, Sweden, Finland and Norway
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
The supplements are made using only vegetarian-sourced ingredients
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
Subscribe To Our Newsletter & Stay Updated
